1. Home
  2. TBPH vs MYD Comparison

TBPH vs MYD Comparison

Compare TBPH & MYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • MYD
  • Stock Information
  • Founded
  • TBPH 2013
  • MYD 1991
  • Country
  • TBPH United States
  • MYD United States
  • Employees
  • TBPH N/A
  • MYD N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • MYD Investment Bankers/Brokers/Service
  • Sector
  • TBPH Health Care
  • MYD Finance
  • Exchange
  • TBPH Nasdaq
  • MYD Nasdaq
  • Market Cap
  • TBPH 485.8M
  • MYD 479.5M
  • IPO Year
  • TBPH N/A
  • MYD N/A
  • Fundamental
  • Price
  • TBPH $9.15
  • MYD $10.71
  • Analyst Decision
  • TBPH Buy
  • MYD
  • Analyst Count
  • TBPH 4
  • MYD 0
  • Target Price
  • TBPH $13.75
  • MYD N/A
  • AVG Volume (30 Days)
  • TBPH 166.7K
  • MYD 253.1K
  • Earning Date
  • TBPH 02-24-2025
  • MYD 01-01-0001
  • Dividend Yield
  • TBPH N/A
  • MYD 4.55%
  • EPS Growth
  • TBPH N/A
  • MYD N/A
  • EPS
  • TBPH N/A
  • MYD N/A
  • Revenue
  • TBPH $63,192,000.00
  • MYD N/A
  • Revenue This Year
  • TBPH $11.41
  • MYD N/A
  • Revenue Next Year
  • TBPH $37.36
  • MYD N/A
  • P/E Ratio
  • TBPH N/A
  • MYD N/A
  • Revenue Growth
  • TBPH 15.93
  • MYD N/A
  • 52 Week Low
  • TBPH $7.44
  • MYD $8.76
  • 52 Week High
  • TBPH $10.44
  • MYD $11.30
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 49.84
  • MYD 51.61
  • Support Level
  • TBPH $8.35
  • MYD $10.42
  • Resistance Level
  • TBPH $8.86
  • MYD $10.66
  • Average True Range (ATR)
  • TBPH 0.29
  • MYD 0.10
  • MACD
  • TBPH -0.05
  • MYD 0.05
  • Stochastic Oscillator
  • TBPH 58.39
  • MYD 97.37

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About MYD Blackrock MuniYield Fund Inc.

Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.

Share on Social Networks: